The Antiandrogenic Effect of Finasteride Against a Mutant Androgen Receptor

The study investigated the antiandrogenic effect of finasteride against a mutant androgen receptor (AR) in prostate cancer cells. The results showed that finasteride was able to inhibit the growth of LNCaP cells, but not VCaP cells. The study also compared the AR antagonistic effect of finasteride to that of bicalutamide, a non-steroidal antiandrogen, and found them to be comparable. The study suggests that finasteride could affect AR signaling beyond limiting the production of DHT, and additional studies are needed to investigate the susceptibility of various AR mutants to finasteride. The study concludes that finasteride could be beneficial in improving the outcome of androgen deprivation therapy for prostate cancer.